Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Long-term Confirmatory Follow up Trial in Highly Sensitized Patients Treated With Imlifidase or Standard of Care in the ConfIdeS (20-HMedIdeS-17) Trial

NCT05714514 is registered in ClinicalTrials.gov with Hansa Biopharma AB as lead sponsor.

NCT NCT05714514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05714514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Long-term Confirmatory Follow up Trial in Highly Sensitized Patients Treated With Imlifidase or Standard of Care in the ConfIdeS (20-HMedIdeS-17) Trial
Lead sponsor
Hansa Biopharma AB
Phase
Observational
Overall status
Active, not recruiting
Start date
April 21, 2023
Completion date
December 31, 2029
Enrollment
64 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplantation in highly sensitized patients